Two years after buying CinCor Pharma for $1.3 billion, AstraZeneca has reported that the main asset in the deal, for uncontrolled or treatment-resistant hypertension, has cleared a phase 3 trial.
Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...
MatrixSeven / file-transfer-go Public Notifications You must be signed in to change notification settings Fork 392 Star 3k ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback